Camrelizumab Combined With Chemotherapy for Recurrent or Advanced Cervical Neuroendocrine Carcinomas

NCT04635956 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Chemotherapy
Anti-pd-1 Antibody
Cervical Neuroendocrine Carcinoma
Adverse Drug Event
Recurrent Cervical Carcinoma
Advanced Cervical Carcinoma
Objective Response Rate

Interventions

DRUG: Drug therapy

Sponsor

Lei Li